ArtNr |
S1130-10000 |
Hersteller |
Selleckchem
|
CAS-Nr. |
781661-94-7 |
Menge |
10 g |
Quantity options |
10 mg
100mg
1g
10 g
10mM/1mL
200 mg
25mg
5mg
50 mg
5 g
|
Kategorie |
|
Typ |
Inhibitors |
Specific against |
other |
Smiles |
CC1=[N+](C2=C(N1CCOC)C(=O)C3=CC=CC=C3C2=O)CC4=NC=CN=C4.[Br-] |
ECLASS 10.1 |
32160490 |
ECLASS 11.0 |
32160490 |
UNSPSC |
12000000 |
Alias |
Survivin;Survivin |
Similar products |
YM155 |
Lieferbar |
|
Storage Conditions |
2 years -80 in solvent |
Molecular Weight |
443, 29 |
Administration |
Subcutaneous injection as a 3-day continuous infusion per week for 3 weeks by an implanted micro-osmotic pump |
Animal Models |
PC-3 s.c. (orthotopic) xenografts in male nude mice (BALB/c nu/nu) |
Cell lines |
Hormone refractory prostate cancer cell lines (PC-3, PPC-1, DU145, TSU-Pr1 and 22Rv1), and malignant melanoma cell lines (SK-MEL-5 and A375) |
Clinical Trials |
YM155 is currently in Phase II clinical trial in advanced non-small cell lung carcinoma. |
Concentrations |
ca. 100 nM |
Dosages |
5 mg/kg |
Formulation |
Dissolved and diluted in saline immediately before administration |
IC50 |
0.54 nM [1], 0.54 nM [1], 0.54 nM [1], 0.54 nM [1], 0.54 nM [1], 0.54 nM [1] |
In vitro |
YM155 is not sensitive to survivn gene promoter-driven luciferase reporter activity even at 30 uM. YM155 significantly inhibits endogenous survivin expression in PC-3 and PPC-1 human HRPC cells with deficient p53 through transcriptional inhibition of the survivin gene promoter. On the contrary YM155 shows no sufficient effect on protein expression of c-IAP2, XIAP, Bcl-2, Bcl-xL, Bad, alpha-actin, and beta-tubulin at 100 nM. YM155 indicates great apoptosis in human cancer cell lines including PC-3 and PPC-1 with a concomitant increase in caspase-3 activity. YM155 potently inhibits human cancer cell lines (mutated or truncated p53) including PC-3, PPC-1, DU145, TSU-Pr1, 22Rv1, SK-MEL-5 and A375 with IC50 from 2.3 to 11 nM, respectively. [1] YM155 increases the sensitivity of NSCLC cells to gamma-radiation. The combination of YM155 and gamma-radiation increases both the number of apoptotic cells and the activity of caspase-3. YM155 delays the repair of radiation-induced double-strand breaks in nuclear DNA. [2] |
In vivo |
YM155 completely inhibits the tumor growth of PC-3 s.c. xenografted prostate tumors at doses of 3 and 10 mg/kg, without body weight loss and blood cell count decrease. Pharmacokinetic analysis shows that YM155 is highly distributed to tumor tissue. Moreover, YM155 shows 80% TGI at a dose of 5 mg/kg in PC-3 orthotopic xenografts. [1] The combination therapy with YM155 and gamma-radiation shows great antitumor activity against H460 or Calu6 xenografts in nude mice. [2] |
Incubation Time |
48 hours |
Kinase Assay |
Promoter-luciferase reporter assay, A 2, 767-bp sequence of human survivin gene promoter is isolated from human genomic DNA by PCR using Pyrobest polymerase and the following primers: 5'-GCGCGCTCGAGTCTAGACATGCGGATATATTC-3' and 5'-GCGCGAA-GCTTTGGCGGTTAATGGCGCGC-3'. The resulting PCR fragment is digested with XhoI/HindIII and ligated into the XhoI/HindIII cleavage site of the pGL3-Basic vector. The resulting plasmid is named pSUR-luc. DNA sequencing is done on all amplified sequences by a DNA sequencer. The activity of pSUR-luc is confirmed by luciferase assay with transiently transfected HeLa-S3 cells. Luciferase assay is done. The pGL3 control vector, which contains the SV40 promoter and enhancer sequences, is used. HeLa cells are stably transfected with pSUR-luc and pSV2bsr by Lipofect-AMINE 2000. After blasticidin selection at 10 ug/mL, a single colony is chosen based on appropriate luciferase signals and genetic stability over time and named HeLa-SURP-luc. CHO cells are stably transfected with pGL3-control and pSV2bsr. After blasticidin selection at 10 ug/mL, a single colony is chosen based on appropriate luciferase signals and genetic stability over time and named CHO-SV40-luc. Stocked cells from the HeLa-SURP-luc and CHO-SV40-luc clones are used for chemical screening and characterization of YM155. YM155 in DMSO are added to the cells, which had been seeded the previous day on 96-well plastic plates at 5, 103 per well. Luciferase activity is measured 24 hours later. IC50 is calculated by logistic analysis. |
Method |
Cells are seeded in 96-well plates at a density of 5-40, 103. YM155 is dissolved in DMSO and added to cells for 48 hours. Then the cell count is determined by sulforhodamine B assay. |
Solubility (25C) |
DMSO 55 mg/mL, Water 89 mg/mL, Ethanol 6 mg/mL |
Information |
Sepantronium Bromide(YM155) is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM in HeLa-SURP-luc and CHO-SV40-luc cells; does not significantly inhibit SV40 promoter activity, but is observed to slightly inhibit the interaction of Survivin with XIAP. YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells. Phase 2. |
Chemical Name |
1H-Naphth[2, 3-d]imidazolium, 4, 9-dihydro-1-(2-methoxyethyl)-2-methyl-4, 9-dioxo-3-(2-pyrazinylmethyl)-, bromide (1:1) |
Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.
Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.